GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taisho Pharmaceutical Holdings Co Ltd (TSE:4581) » Definitions » Short Percentage of Float

Taisho Pharmaceutical Holdings Co (TSE:4581) Short Percentage of Float


View and export this data going back to 2011. Start your Free Trial

What is Taisho Pharmaceutical Holdings Co Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of Taisho Pharmaceutical Holdings Co's Short Percentage of Float

For the Drug Manufacturers - Specialty & Generic subindustry, Taisho Pharmaceutical Holdings Co's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taisho Pharmaceutical Holdings Co's Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taisho Pharmaceutical Holdings Co's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Taisho Pharmaceutical Holdings Co's Short Percentage of Float falls into.



Taisho Pharmaceutical Holdings Co (TSE:4581) Business Description

Traded in Other Exchanges
Address
3-24-1 Takada, Toshima-ku, Tokyo, JPN, 170-8655
Taisho Pharmaceutical Holding Co Ltd is a specialty and generic drug manufacturing company. The company maintains two operational segments, Self-Medication and Prescription Pharmaceuticals. The vast majority of Taisho's revenue is derived from its Self-Medication segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The vast majority of sales are generated by sales to external customers in Japan.

Taisho Pharmaceutical Holdings Co (TSE:4581) Headlines

No Headlines